CN101700237A - 装有氢氯噻嗪固体制剂和阿利吉仑固体制剂的组合胶囊 - Google Patents
装有氢氯噻嗪固体制剂和阿利吉仑固体制剂的组合胶囊 Download PDFInfo
- Publication number
- CN101700237A CN101700237A CN200910307780A CN200910307780A CN101700237A CN 101700237 A CN101700237 A CN 101700237A CN 200910307780 A CN200910307780 A CN 200910307780A CN 200910307780 A CN200910307780 A CN 200910307780A CN 101700237 A CN101700237 A CN 101700237A
- Authority
- CN
- China
- Prior art keywords
- capsule
- solid preparation
- aliskiren
- hydrochlorothiazide
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 79
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 title claims abstract description 44
- 229960004601 aliskiren Drugs 0.000 title claims abstract description 44
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229960002003 hydrochlorothiazide Drugs 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 239000007787 solid Substances 0.000 title claims abstract description 31
- 238000000576 coating method Methods 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000006227 byproduct Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000008859 change Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940044478 aliskiren 150 mg Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229940082195 hydrochlorothiazide 12.5 mg Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940075708 aliskiren and hydrochlorothiazide Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
第一阿利吉仑mg | 颜色 | 第二阿利吉仑mg | 颜色 | 氢氯噻嗪mg | 颜色 | |
实施例2 | 150 | 红色片 | 150 | 黑色片 | 25 | 白色片 |
阿利吉仑mg | 颜色 | 氢氯噻嗪mg | 颜色 | |
实施例4 | 150 | 红色片 | 25 | 白色片 |
实施例1 | 实施例2 | ||
0天含量 | 阿利吉仑(%) | 99.18 | 99.65 |
氢氯噻嗪(%) | 99.36 | 99.76 | |
5天含量 | 阿利吉仑(%) | 99.43 | 99.90 |
氢氯噻嗪(%) | 99.32 | 100.1 | |
10天含量 | 阿利吉仑(%) | 99.18 | 99.25 |
氢氯噻嗪(%) | 99.93 | 100.1 |
实施例1 | 实施例2 | ||
0天含量 | 阿利吉仑(%) | 99.18 | 99.65 |
氢氯噻嗪(%) | 99.36 | 99.76 | |
5天含量 | 阿利吉仑(%) | 99.43 | 99.63 |
氢氯噻嗪(%) | 99.46 | 99.37 | |
10天含量 | 阿利吉仑(%) | 99.17 | 99.25 |
氢氯噻嗪(%) | 99.38 | 99.46 |
实施例1 | 实施例2 | ||
0天含量 | 阿利吉仑(%) | 99.18 | 99.65 |
氢氯噻嗪(%) | 99.36 | 99.76 | |
5天含量 | 阿利吉仑(%) | 99.42 | 99.64 |
氢氯噻嗪(%) | 99.38 | 99.35 | |
10天含量 | 阿利吉仑(%) | 99.15 | 99.27 |
氢氯噻嗪(%) | 99.33 | 99.44 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910307780A CN101700237A (zh) | 2009-09-26 | 2009-09-26 | 装有氢氯噻嗪固体制剂和阿利吉仑固体制剂的组合胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910307780A CN101700237A (zh) | 2009-09-26 | 2009-09-26 | 装有氢氯噻嗪固体制剂和阿利吉仑固体制剂的组合胶囊 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101700237A true CN101700237A (zh) | 2010-05-05 |
Family
ID=42155180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910307780A Pending CN101700237A (zh) | 2009-09-26 | 2009-09-26 | 装有氢氯噻嗪固体制剂和阿利吉仑固体制剂的组合胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101700237A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102247344A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血压组合物 |
-
2009
- 2009-09-26 CN CN200910307780A patent/CN101700237A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102247344A (zh) * | 2011-05-30 | 2011-11-23 | 北京阜康仁生物制药科技有限公司 | 一种新型降血压组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bockbrader et al. | A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin | |
CN102118970A (zh) | 包含多巴胺受体配体的药物制剂 | |
CN101700237A (zh) | 装有氢氯噻嗪固体制剂和阿利吉仑固体制剂的组合胶囊 | |
CN202010289U (zh) | 装有氢氯噻嗪固体制剂和阿利吉仑固体制剂的组合胶囊 | |
Thumma et al. | Compatibility studies of promethazine hydrochloride with tablet excipients by means of thermal and non-thermal methods | |
CN203970949U (zh) | 装有奥美拉唑片和碳酸氢钠片的片剂胶囊 | |
CN202168960U (zh) | 含有奥美沙坦酯、氨氯地平和氢氯噻嗪的复方制剂 | |
CN201701513U (zh) | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 | |
CN201578611U (zh) | 装有氢氯噻嗪固体制剂和贝那普利固体制剂的组合胶囊 | |
CN201701514U (zh) | 装有罗红霉素片和盐酸氨溴索片的片剂胶囊 | |
CN201524269U (zh) | 装有瑞拉格脲固体制剂和二甲双胍固体制剂的组合胶囊 | |
CN102274231A (zh) | 装有洛匹那韦片和利托那韦片剂胶囊 | |
CN201701511U (zh) | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 | |
CN202146449U (zh) | 装有洛匹那韦片和利托那韦片剂胶囊 | |
CN102283848A (zh) | 含有奥美沙坦酯、氨氯地平和氢氯噻嗪的复方制剂 | |
CN102008478A (zh) | 装有头孢氨苄片和盐酸氨溴索片的片剂胶囊 | |
CN103356623A (zh) | 复方富马酸亚铁和叶酸新型胶囊 | |
CN202568926U (zh) | 装有阿格列汀固体制剂和吡格列酮固体制剂的片剂胶囊 | |
CN202568934U (zh) | 装有格列吡嗪固体制剂和二甲双胍固体制剂的片剂胶囊 | |
CN101700238A (zh) | 装有氢氯噻嗪固体制剂和贝那普利固体制剂的组合胶囊 | |
CN201524270U (zh) | 装有甘草酸苷固体制剂和甘氨酸固体制剂的组合胶囊 | |
CN102008467A (zh) | 装有阿莫西林片和盐酸氨溴索片的片剂胶囊 | |
CN201701512U (zh) | 装有氯雷他定片和盐酸氨溴索片的片剂胶囊 | |
CN103356621A (zh) | 装有阿格列汀固体制剂和吡格列酮固体制剂的新型胶囊 | |
CN102018694A (zh) | 装有硫酸沙丁胺醇片和盐酸氨溴索片的片剂胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG FUHE HUAXING PHARMACY GROUP CO., LTD. Free format text: FORMER OWNER: WU GUANGYAN Effective date: 20110518 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20110518 Address after: 151100 Heilongjiang Zhaodong Taiping Road 34, Heilongjiang Dilong pharmaceutical Limited by Share Ltd Applicant after: Heilongjiang Fuhe Huaxing Pharmaceutical Group Co., Ltd. Address before: 151100 Heilongjiang Zhaodong Taiping Road 34, Heilongjiang Dilong pharmaceutical Limited by Share Ltd Applicant before: Wu Guangyan |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100505 |